#China #Hangzhou #LP-003 #Altruist Biologics #LongBio Pharma

Altruist Biologics and LongBio Pharma: A Groundbreaking Achievement in Allergy Treatment

Introduction

On September 14, 2026, Altruist Biologics, a leading contract development and manufacturing organization (CDMO), announced the acceptance of LongBio Pharma's Biologics License Application (BLA) for LP-003 by the China National Medical Products Administration (NMPA). This acceptance marks a remarkable milestone, placing LP-003 at the forefront as China's first anti-IgE biologic candidate approved for seasonal allergic rhinitis treatment.

Significance of the BLA Acceptance

LongBio Pharma's LP-003 is a next-generation anti-IgE monoclonal antibody specifically designed to neutralize free immunoglobulin E (IgE) in the body. Allergic rhinitis, affecting over 200 million individuals in China, severely hampers daily activities and affects quality of life due to symptoms such as sneezing, nasal congestion, and rhinorrhea. With no approved targeted anti-IgE treatments currently available in China, this BLA acceptance fills a significant void in the market and addresses substantial unmet clinical needs.

The innovative mechanism of LP-003 aims to disrupt the allergic response by binding to free IgE, thereby blocking its interaction with the high-affinity IgE receptor (FcεRI). This targeted approach enables a more efficient response to allergic triggers, promising a better quality of life for many sufferers.

Support from Altruist Biologics

Altruist Biologics played an integral role in LP-003's journey from concept to BLA submission. The collaboration encompassed comprehensive support throughout the Chemistry, Manufacturing, and Controls (CMC) lifecycle, including process development, large-scale Good Manufacturing Practice (GMP) manufacturing, and regulatory submissions. Dr. Kaisong Zhou, Chairman and CEO of Altruist Biologics, expressed pride in the partnership and acknowledged the collaborative effort needed to navigate the complexities of drug development and regulatory compliance.

Altruist's commitment to leveraging its expertise in biologics manufacturing and maintaining rigorous quality standards facilitated the smooth progression of LP-003 through the various phases of development. The acceptance of the BLA not only exemplifies LongBio's dedication to addressing allergic and autoimmune diseases but also showcases Altruist's ability to support clients in achieving significant milestones.

Future Prospects

Dr. Liu Heng, Co-Founder, Chairman, and CEO of LongBio Pharma, highlighted the importance of this achievement, stating that it represents a significant step towards providing innovative treatment solutions for allergic diseases in China. With multiple ongoing clinical trials for LP-003, the company aims to bring this groundbreaking therapy to market, thereby potentially transforming the treatment landscape for millions.

This advancement is supported by Altruist Biologics, which has successfully assisted in over 100 biologics programs, addressing regulatory submissions like IND and NDA, while adhering to strict international quality benchmarks. The company’s longstanding commitment to operational excellence ensures optimal development environments for emerging therapies.

Conclusion

The acceptance of LP-003's BLA stands as a testament to the efficacy of collaborative efforts in addressing critical healthcare needs. Both Altruist Biologics and LongBio Pharma are poised to make significant impacts in the field of allergy treatments, indicating a hopeful future for patients suffering from allergic rhinitis. With continued advancements and close cooperation with regulatory bodies, LP-003 is primed to become a game-changer in the biopharmaceutical landscape.

For further insights into Altruist Biologics' comprehensive service offerings, visit their official website: www.altruistbio.com.